On December 30, 2025, Atara Biotherapeutics, Inc., (the "Company") reported to have entered into the Fourth Amendment (the "Amendment") to the Amended and Restated Commercialization Agreement dated October 31, 2023 (the "Agreement") with Pierre Fabre Medicament ("Pierre Fabre"). Under the terms of the Amendment, the Company has agreed to reduce the aggregate amount of potential milestone payments payable by Pierre Fabre to the Company upon achieving certain regulatory milestones relating to the approval by the FDA of a BLA for tab-cel from $40.0 million to $31.0 million for the right to receive an additional $15.0 million potential milestone payment from Pierre Fabre to the Company upon achieving a certain commercial milestone.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The foregoing summary of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 1.01.

(Filing, 8-K, Atara Biotherapeutics, DEC 30, 2025, View Source [SID1234661683])